Harmony Biosciences price target raised to $33 from $31 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Harmony Biosciences (HRMY) to $33 from $31 and keeps an Underperform rating on the shares. The Q4 update was “largely as expected,” though the company did announce a Wakix patent settlement for 2030 entry, the analyst noted. However, six other generic challengers remain with a trial in 2026, the analyst noted.